Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 42 | 2023 | 3362 | 3.320 |
Why?
|
| Contrast Media | 31 | 2022 | 1078 | 1.820 |
Why?
|
| Breast Neoplasms | 22 | 2022 | 2903 | 1.750 |
Why?
|
| Breast | 12 | 2022 | 288 | 1.690 |
Why?
|
| Prostatic Neoplasms | 18 | 2022 | 1721 | 1.600 |
Why?
|
| Image Enhancement | 15 | 2021 | 563 | 1.520 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 9 | 2022 | 294 | 1.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 14 | 2019 | 663 | 1.090 |
Why?
|
| Algorithms | 12 | 2018 | 1830 | 0.900 |
Why?
|
| Image Processing, Computer-Assisted | 11 | 2022 | 1204 | 0.880 |
Why?
|
| Fourier Analysis | 5 | 2016 | 125 | 0.810 |
Why?
|
| Prostate | 6 | 2022 | 378 | 0.810 |
Why?
|
| Artifacts | 1 | 2023 | 244 | 0.790 |
Why?
|
| Echo-Planar Imaging | 5 | 2017 | 52 | 0.760 |
Why?
|
| Water | 4 | 2012 | 277 | 0.740 |
Why?
|
| Phantoms, Imaging | 5 | 2023 | 429 | 0.610 |
Why?
|
| Reproducibility of Results | 18 | 2021 | 2705 | 0.550 |
Why?
|
| Signal-To-Noise Ratio | 5 | 2021 | 96 | 0.530 |
Why?
|
| Ejaculation | 1 | 2014 | 9 | 0.490 |
Why?
|
| Gadolinium DTPA | 11 | 2015 | 261 | 0.480 |
Why?
|
| Gadolinium | 2 | 2019 | 103 | 0.460 |
Why?
|
| Sensitivity and Specificity | 15 | 2022 | 1991 | 0.440 |
Why?
|
| Pilot Projects | 7 | 2021 | 839 | 0.390 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 199 | 0.370 |
Why?
|
| Mammography | 1 | 2012 | 463 | 0.340 |
Why?
|
| Biopsy | 5 | 2022 | 1163 | 0.340 |
Why?
|
| Breast Diseases | 2 | 2011 | 97 | 0.340 |
Why?
|
| Humans | 47 | 2022 | 86643 | 0.330 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2009 | 579 | 0.310 |
Why?
|
| Prospective Studies | 7 | 2022 | 4213 | 0.280 |
Why?
|
| Female | 27 | 2022 | 44532 | 0.280 |
Why?
|
| Middle Aged | 24 | 2022 | 25028 | 0.250 |
Why?
|
| Adult | 18 | 2022 | 25648 | 0.230 |
Why?
|
| Male | 23 | 2022 | 40965 | 0.230 |
Why?
|
| Biomarkers, Tumor | 3 | 2013 | 1464 | 0.230 |
Why?
|
| Aged | 17 | 2022 | 18415 | 0.220 |
Why?
|
| Kidney Neoplasms | 3 | 2016 | 621 | 0.200 |
Why?
|
| Diagnosis, Differential | 5 | 2022 | 1565 | 0.200 |
Why?
|
| Magnets | 1 | 2021 | 14 | 0.200 |
Why?
|
| Neovascularization, Pathologic | 3 | 2015 | 353 | 0.200 |
Why?
|
| Breast Density | 2 | 2020 | 31 | 0.190 |
Why?
|
| Organometallic Compounds | 2 | 2015 | 132 | 0.190 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2016 | 311 | 0.180 |
Why?
|
| Pancreas | 1 | 2021 | 239 | 0.180 |
Why?
|
| Hyperthermia, Induced | 1 | 2020 | 73 | 0.180 |
Why?
|
| Fibroadenoma | 1 | 2019 | 9 | 0.180 |
Why?
|
| Subtraction Technique | 3 | 2009 | 133 | 0.170 |
Why?
|
| Neoplasm Grading | 3 | 2016 | 357 | 0.170 |
Why?
|
| Laser Therapy | 1 | 2020 | 142 | 0.170 |
Why?
|
| Healthy Volunteers | 2 | 2021 | 143 | 0.160 |
Why?
|
| Arteries | 2 | 2018 | 176 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2601 | 0.150 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 466 | 0.150 |
Why?
|
| Meglumine | 1 | 2015 | 39 | 0.140 |
Why?
|
| Sulfonamides | 1 | 2016 | 300 | 0.120 |
Why?
|
| Pyrimidines | 1 | 2016 | 370 | 0.120 |
Why?
|
| Pyrroles | 2 | 2004 | 184 | 0.110 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2015 | 262 | 0.110 |
Why?
|
| Software | 1 | 2017 | 654 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2013 | 110 | 0.110 |
Why?
|
| Indoles | 2 | 2004 | 318 | 0.110 |
Why?
|
| Fats | 1 | 2011 | 12 | 0.100 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 6509 | 0.100 |
Why?
|
| Needs Assessment | 1 | 2012 | 154 | 0.100 |
Why?
|
| Prostate-Specific Antigen | 1 | 2013 | 353 | 0.100 |
Why?
|
| Muscle, Skeletal | 2 | 2004 | 449 | 0.100 |
Why?
|
| Oils | 1 | 2010 | 6 | 0.100 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 332 | 0.100 |
Why?
|
| Adipose Tissue | 2 | 2017 | 240 | 0.090 |
Why?
|
| Models, Biological | 5 | 2015 | 1749 | 0.090 |
Why?
|
| Melanoma | 2 | 2004 | 459 | 0.090 |
Why?
|
| Computer Simulation | 4 | 2021 | 1078 | 0.090 |
Why?
|
| Feasibility Studies | 2 | 2016 | 751 | 0.090 |
Why?
|
| Reference Standards | 1 | 2010 | 159 | 0.090 |
Why?
|
| Radiography | 1 | 2011 | 813 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 157 | 0.080 |
Why?
|
| Microvessels | 1 | 2009 | 70 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2008 | 66 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2022 | 8489 | 0.080 |
Why?
|
| Time Factors | 4 | 2010 | 5210 | 0.070 |
Why?
|
| Pyridines | 1 | 2008 | 310 | 0.070 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2006 | 14 | 0.070 |
Why?
|
| Kinetics | 2 | 2022 | 1513 | 0.060 |
Why?
|
| Liver | 2 | 2013 | 1230 | 0.060 |
Why?
|
| Body Water | 1 | 2004 | 35 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2008 | 426 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2004 | 81 | 0.060 |
Why?
|
| Muscle Neoplasms | 1 | 2004 | 18 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2006 | 482 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 1961 | 0.060 |
Why?
|
| Neoplasm Transplantation | 1 | 2004 | 391 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 302 | 0.050 |
Why?
|
| Motion | 1 | 2022 | 85 | 0.050 |
Why?
|
| Prostatectomy | 2 | 2016 | 471 | 0.050 |
Why?
|
| Reference Values | 2 | 2015 | 674 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2002 | 318 | 0.050 |
Why?
|
| Mesothelioma | 1 | 2004 | 311 | 0.050 |
Why?
|
| Young Adult | 3 | 2019 | 5976 | 0.050 |
Why?
|
| Hormones | 1 | 2021 | 141 | 0.050 |
Why?
|
| ROC Curve | 2 | 2013 | 752 | 0.050 |
Why?
|
| Area Under Curve | 2 | 2013 | 334 | 0.050 |
Why?
|
| Rats | 4 | 2009 | 3990 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 2004 | 556 | 0.040 |
Why?
|
| Indicator Dilution Techniques | 1 | 2019 | 9 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 318 | 0.040 |
Why?
|
| Observer Variation | 1 | 2020 | 602 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2004 | 736 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 1056 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 2360 | 0.040 |
Why?
|
| Time | 1 | 2016 | 77 | 0.040 |
Why?
|
| Indazoles | 1 | 2016 | 68 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 2015 | 121 | 0.030 |
Why?
|
| Spin Labels | 1 | 2015 | 102 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 684 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2016 | 7993 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 912 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2013 | 289 | 0.030 |
Why?
|
| Pattern Recognition, Automated | 1 | 2013 | 217 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2013 | 361 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 1531 | 0.030 |
Why?
|
| Injections | 1 | 2010 | 109 | 0.020 |
Why?
|
| Biological Transport | 1 | 2010 | 396 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 1939 | 0.020 |
Why?
|
| Spectrophotometry | 1 | 2008 | 106 | 0.020 |
Why?
|
| Niacinamide | 1 | 2008 | 116 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 218 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2008 | 114 | 0.020 |
Why?
|
| Injections, Intra-Arterial | 1 | 2007 | 33 | 0.020 |
Why?
|
| Protons | 1 | 2008 | 98 | 0.020 |
Why?
|
| Animals | 4 | 2009 | 26582 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 8981 | 0.020 |
Why?
|
| Information Storage and Retrieval | 1 | 2006 | 120 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 859 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2008 | 1538 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2008 | 574 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2004 | 185 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2008 | 1823 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2004 | 332 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 2426 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 407 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2004 | 464 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2004 | 1041 | 0.010 |
Why?
|
| Glucose | 1 | 2004 | 638 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2004 | 589 | 0.010 |
Why?
|
| Neoplasms | 1 | 2008 | 2898 | 0.010 |
Why?
|